| A B C D E F G H I J K L M N O P Q R S T U V W X Y Z # |
Drug Abuse Survey with Confirmation, Panel 9, Random, Urine
Test CodeCDAU7
Alias/See Also
Epic: LAB13446
Mayo: CDAU7
Mayo: CDAU7
CPT Codes
80307
Includes
REFLEX TESTS
| Test Id | Reporting Name | Available Separately | Always Performed |
|---|---|---|---|
| OPATU | Opiate Confirmation, U | Yes | No |
| AMPHU | Amphetamines Confirmation, U | Yes | No |
| BARBU | Barbiturates Confirmation, U | Yes | No |
| COKEU | Cocaine and metabolite Conf, U | Yes | No |
| ETOH | Ethanol, U | No | No |
| MTDNU | Methadone Confirmation, U | Yes | No |
| PCPU | Phencyclidine Confirmation, U | Yes | No |
| THCU | Carboxy-THC Confirmation, U | Yes | No |
| BNZU | Benzodiazepines Confirmation, U | Yes | No |
Preferred Specimen
Specimen Type: Urine
Collection Container: Sterile container
Specimen Volume: 30 mL
Minimum Volume
15 mL
Instructions
Collection Instructions:
Additional Information:
- Collect a random urine specimen.
- Submit 30 mL in 1 plastic bottle.
- No preservative.
Additional Information:
- No specimen substitutions.
- Additional drug panels and specific requests are available. Call 800-533-1710 or 507-266-5700.
- Submitting less than 30 mL will compromise our ability to perform all necessary testing.
Transport Container
Plastic, 60-mL urine bottle
Specimen Stability
| Specimen Type | Temperature | Time | Special Container |
|---|---|---|---|
| Urine | Refrigerated (preferred) | 7 days | |
| Frozen | 14 days |
Reject Criteria (Eg, hemolysis? Lipemia? Thaw/Other?)
All specimens will be evaluated at Mayo Clinic Laboratories for test suitability.
Methodology
CDAU7: Alcohol Screened by an Enzymatic Assay/All Others Screened by Immunoassay
ETOH: Gas Chromatography-Flame Ionization Detector (GC-FID)
Setup Schedule
Monday through Saturday
Report Available
Same day/1 to 2 days
Limitations
CAUTIONS
Not intended for use in employment-related testing.
The test does not screen for drug classes other than those listed above. More comprehensive screening is available using the serum or urine drug screens (DSS / Drug Screen, Prescription/OTC, Serum or PDSU / Drug Screen, Prescription/OTC, Urine).
Not intended for use in employment-related testing.
The test does not screen for drug classes other than those listed above. More comprehensive screening is available using the serum or urine drug screens (DSS / Drug Screen, Prescription/OTC, Serum or PDSU / Drug Screen, Prescription/OTC, Urine).
Reference Range
REFERENCE VALUES
Negative
Screening cutoff concentrations
Amphetamines: 500 ng/mL
Barbiturates: 200 ng/mL
Benzodiazepines: 100 ng/mL
Cocaine (benzoylecgonine-cocaine metabolite): 150 ng/mL
Ethanol: 10 mg/dL
Methadone metabolite: 300 ng/mL
Opiates: 300 ng/mL
Phencyclidine: 25 ng/mL
Tetrahydrocannabinol carboxylic acid: 50 ng/mL
This report is intended for use in clinical monitoring or management of patients. It is not intended for use in employment-related testing.
INTERPRETATION
A positive result indicates that the patient has used the drugs detected in the recent past. See individual tests (eg, AMPHU / Amphetamines Confirmation, Urine) for more information.
For information about drug testing, including estimated detection times, see Drugs of Abuse Testing at https://www.mayocliniclabs.com/test-info/drug-book/index.html
Negative
Screening cutoff concentrations
Amphetamines: 500 ng/mL
Barbiturates: 200 ng/mL
Benzodiazepines: 100 ng/mL
Cocaine (benzoylecgonine-cocaine metabolite): 150 ng/mL
Ethanol: 10 mg/dL
Methadone metabolite: 300 ng/mL
Opiates: 300 ng/mL
Phencyclidine: 25 ng/mL
Tetrahydrocannabinol carboxylic acid: 50 ng/mL
This report is intended for use in clinical monitoring or management of patients. It is not intended for use in employment-related testing.
INTERPRETATION
A positive result indicates that the patient has used the drugs detected in the recent past. See individual tests (eg, AMPHU / Amphetamines Confirmation, Urine) for more information.
For information about drug testing, including estimated detection times, see Drugs of Abuse Testing at https://www.mayocliniclabs.com/test-info/drug-book/index.html
Clinical Significance
USEFUL FOR
Detecting drug abuse involving, amphetamines, barbiturates, benzodiazepines, cocaine, ethanol, methadone, opiates, phencyclidine, and tetrahydrocannabinol
This test is intended to be used in a setting where the test results can be used definitively to make a diagnosis.
TESTING ALGORITHM
Testing begins with screening tests for alcohol and drugs of abuse. Positives are confirmed and quantitated by definitive methods (gas chromatography-flame ionization detector for ethanol; gas chromatography-mass spectrometry for barbiturates, benzodiazepines, cocaine and metabolites, methadone, phencyclidine, and tetrahydrocannabinol metabolite) at an additional charge. Amphetamines and opiates that screen positive will be quantified with liquid chromatography-tandem mass spectrometry at an additional charge.
CLINICAL INFORMATION
This assay was designed to screen by immunoassay and confirm by gas chromatography-mass spectrometry (GC-MS), gas chromatography-flame ionization detection (GC-FID), or liquid chromatography-tandem mass spectrometry (LC-MS/MS) for the following drugs:
-Amphetamines
-Barbiturates
-Benzodiazepines
-Cocaine
-Ethanol
-Opiates
-Methadone
-Phencyclidine
-Tetrahydrocannabinol
This test represents the coupling of an immunoassay screen with an automatic confirmation of all positive results by the definitive assay available and described in each individual reflex test (eg, AMPHU / Amphetamines Confirmation, Urine). All positive screening results are confirmed by GC-MS, GC-FID, or LC-MS/MS and quantitated before a positive result is reported.
Detecting drug abuse involving, amphetamines, barbiturates, benzodiazepines, cocaine, ethanol, methadone, opiates, phencyclidine, and tetrahydrocannabinol
This test is intended to be used in a setting where the test results can be used definitively to make a diagnosis.
TESTING ALGORITHM
Testing begins with screening tests for alcohol and drugs of abuse. Positives are confirmed and quantitated by definitive methods (gas chromatography-flame ionization detector for ethanol; gas chromatography-mass spectrometry for barbiturates, benzodiazepines, cocaine and metabolites, methadone, phencyclidine, and tetrahydrocannabinol metabolite) at an additional charge. Amphetamines and opiates that screen positive will be quantified with liquid chromatography-tandem mass spectrometry at an additional charge.
CLINICAL INFORMATION
This assay was designed to screen by immunoassay and confirm by gas chromatography-mass spectrometry (GC-MS), gas chromatography-flame ionization detection (GC-FID), or liquid chromatography-tandem mass spectrometry (LC-MS/MS) for the following drugs:
-Amphetamines
-Barbiturates
-Benzodiazepines
-Cocaine
-Ethanol
-Opiates
-Methadone
-Phencyclidine
-Tetrahydrocannabinol
This test represents the coupling of an immunoassay screen with an automatic confirmation of all positive results by the definitive assay available and described in each individual reflex test (eg, AMPHU / Amphetamines Confirmation, Urine). All positive screening results are confirmed by GC-MS, GC-FID, or LC-MS/MS and quantitated before a positive result is reported.
Performing Laboratory
Mayo Clinic Laboratories - Rochester
3050 Superior Drive NW
Rochester, MN 55901
Additional Information
Drug Abuse Survey with Confirmation, Panel 9, Random, Urine
Last Updated: July 20, 2023
Last Review: N. Wolford, July 20, 2023